Formulate great-tasting fizzy tablets and powders

Manufacturers can now overcome challenges in effervescent dosage production with Beneo’s galenIQ 721 filler-binder. This excipient is easy to use and has improved technical properties.

To improve the taste and stability of effervescent tablets and powders, Beneo presents galenIQ 721. The filler-binder meets current industry demands for patient-centric product development solutions, enabling pharma and nutraceutical manufacturers to develop patient-friendly products for those who have difficulty swallowing standard tablets. As a non-hygroscopic, water-soluble and directly compressible excipient, galenIQ 721 also provides high content uniformity and production efficiency for effervescent applications.

A convenient and appealing dosage form

Effervescent powders and tablets offer a more convenient way to deliver medicines or dietary supplements. They dissolve upon contact with water to release carbon dioxide and create a medicated drink. In addition, they can be used to formulate pharmaceuticals that are difficult to digest, cause stomach or oesophageal irritation or rely on a rapid onset of action, such as analgesics.

Overcoming manufacturing challenges

While the dosage form is highly convenient, manufacturing effervescents can be challenging. A non-hygroscopic, direct compression filler-binder such as galenIQ 721 is needed to produce highly stable tablets. This excipient ensures high content uniformity and facilitates production. It also has a sugar-like taste profile, a pleasant mouthfeel and can enhance the palatability of effervescent formulations. Available throughout Southern Africa from Savannah Fine Chemicals, galenIQ 721 is non-cariogenic, sweet and tooth friendly.

Enhanced product development

Dr Maj-Britt Cepok, head of business development, pharma, Beneo, comments: “Fizzy tablets are ideally suited to administer a wide range of light- and oxygen-sensitive active ingredients and those which require a large dose. In addition, effervescent preparations are more appealing to consumers than traditional dosage forms. galenIQ 721 helps manufacturers to tap into this market and enhance their development programmes.”